Merck ltd
The stock showed up as promising while using a filter to identify companies with more then 5 % dividend yield
The analysis with the bajkowski excel gave a surprisingly strong projection of 25.1 % based on historical growth and 24.5 % growth prospect on sustainable growth rate prompting further interest.
A check on the company website
http://www.merck.co.in/investor/index.html reveled this
Sales fell by 31% to Rs.704 million. The profit before taxes fell by 26% to Rs. 229 million. Earnings after taxes fell by 14% to Rs.159 million. Sales & Profit fell due to sale of Life Science and Analytics (excluding Bulk Drug) Business in the year 2006. An amount of Rs.22.1 million was added to the fixed assets during Jan-Mar 2007. The company has investments in Bank Deposits and Liquid funds of Rs.3,054 million.
A news article of interest
Merck, the Indian subsidiary of the German pharma major Merck KgaA, is all set to sell off its life science and analytics businesses to its wholly-owned subsidiary in India, Merck Specialties. The transfer, it is learnt, will take away a substantial part of the business from the listed company of Merck in India.
http://economictimes.indiatimes.com..._sciences_unit_to_arm/articleshow/1359150.cms
The start of a 100% subsidy Merck Specialties in India seems to be dampen the prospects of the Merck ltd in which the parent company has a 51 % share
Further searched in internet also revealed that they are the only manufacturer of vitamin E in India you may also check the reports about the company by way2wealth.com
For future valuation of Merck we have to take in to consideration the sale of the LS&A unit the revised valuations with 30% lesser sales and 26 % drop in profit a rough calculation gives 33.3 EPS for the year and at the market price of 410 its trading at 12 times which is at the lower end of the companies historical PE.
A industry comparison shows that Merck is valued attractively to others
With the large cash poison the company is in the lookout for acquisition which can provide a trigger in the medium term. The cash position of Rs180 per share will also cushion the downside.
The annual report says that substantial portion of the vitamin E raw material is imported and if the treading is in $ the recent developments can help in bringing down the cost
Risk factors
Cheap imports of vitamin E from China
Diminishing Support form parent company
Failure of new products launches
regards
Note: this is the first time I have identified a company based on my own criterias. Please dont take it as an recommendation but would like to have your comments to know if I m in the right direction